These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 26024755)

  • 41. Alpha-naphthoflavone attenuates non-alcoholic fatty liver disease in oleic acid-treated HepG2 hepatocytes and in high fat diet-fed mice.
    Xia H; Zhu X; Zhang X; Jiang H; Li B; Wang Z; Li D; Jin Y
    Biomed Pharmacother; 2019 Oct; 118():109287. PubMed ID: 31401392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MiR-146b attenuates high-fat diet-induced non-alcoholic steatohepatitis in mice.
    Jiang W; Liu J; Dai Y; Zhou N; Ji C; Li X
    J Gastroenterol Hepatol; 2015 May; 30(5):933-43. PubMed ID: 25559563
    [TBL] [Abstract][Full Text] [Related]  

  • 43. β-patchoulene protects against non-alcoholic steatohepatitis via interrupting the vicious circle among oxidative stress, histanoxia and lipid accumulation in rats.
    Luo H; Xu N; Wu J; Gan Y; Chen L; Guan F; Li M; Li Y; Chen J; Su Z; Liu Y
    Int Immunopharmacol; 2021 Sep; 98():107915. PubMed ID: 34198236
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dihydromyricetin Ameliorates Nonalcoholic Fatty Liver Disease by Improving Mitochondrial Respiratory Capacity and Redox Homeostasis Through Modulation of SIRT3 Signaling.
    Zeng X; Yang J; Hu O; Huang J; Ran L; Chen M; Zhang Y; Zhou X; Zhu J; Zhang Q; Yi L; Mi M
    Antioxid Redox Signal; 2019 Jan; 30(2):163-183. PubMed ID: 29310441
    [No Abstract]   [Full Text] [Related]  

  • 45. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats.
    Zhao X; Xue J; Wang XL; Zhang Y; Deng M; Xie ML
    Int Immunopharmacol; 2014 Sep; 22(1):176-81. PubMed ID: 24993341
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tyrosol Attenuates High Fat Diet-Induced Hepatic Oxidative Stress: Potential Involvement of Cystathionine β-Synthase and Cystathionine γ-Lyase.
    Sarna LK; Sid V; Wang P; Siow YL; House JD; O K
    Lipids; 2016 May; 51(5):583-90. PubMed ID: 26518313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.
    Takahara I; Akazawa Y; Tabuchi M; Matsuda K; Miyaaki H; Kido Y; Kanda Y; Taura N; Ohnita K; Takeshima F; Sakai Y; Eguchi S; Nakashima M; Nakao K
    PLoS One; 2017; 12(3):e0170591. PubMed ID: 28278289
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis.
    Martínez L; Torres S; Baulies A; Alarcón-Vila C; Elena M; Fabriàs G; Casas J; Caballeria J; Fernandez-Checa JC; García-Ruiz C
    Oncotarget; 2015 Dec; 6(39):41479-96. PubMed ID: 26539645
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pluripotent Stem Cell-Derived Hepatocytes Phenotypic Screening Reveals Small Molecules Targeting the CDK2/4-C/EBPα/DGAT2 Pathway Preventing ER-Stress Induced Lipid Accumulation.
    Parafati M; Bae SH; Kirby RJ; Fitzek M; Iyer P; Engkvist O; Smith DM; Malany S
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33334026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Decoding cell death signals in liver inflammation.
    Brenner C; Galluzzi L; Kepp O; Kroemer G
    J Hepatol; 2013 Sep; 59(3):583-94. PubMed ID: 23567086
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The beneficial effects of resveratrol on steatosis and mitochondrial oxidative stress in HepG2 cells.
    Izdebska M; Piątkowska-Chmiel I; Korolczuk A; Herbet M; Gawrońska-Grzywacz M; Gieroba R; Sysa M; Czajkowska-Bania K; Cygal M; Korga A; Dudka J
    Can J Physiol Pharmacol; 2017 Dec; 95(12):1442-1453. PubMed ID: 28759727
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Honokiol activates the LKB1-AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes.
    Seo MS; Kim JH; Kim HJ; Chang KC; Park SW
    Toxicol Appl Pharmacol; 2015 Apr; 284(2):113-24. PubMed ID: 25737164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
    Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
    Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic steatohepatitis in mice.
    Kroy DC; Schumacher F; Ramadori P; Hatting M; Bergheim I; Gassler N; Boekschoten MV; Müller M; Streetz KL; Trautwein C
    J Hepatol; 2014 Oct; 61(4):883-90. PubMed ID: 24845607
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metformin prevents ischemia reperfusion-induced oxidative stress in the fatty liver by attenuation of reactive oxygen species formation.
    Cahova M; Palenickova E; Dankova H; Sticova E; Burian M; Drahota Z; Cervinkova Z; Kucera O; Gladkova C; Stopka P; Krizova J; Papackova Z; Oliyarnyk O; Kazdova L
    Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(2):G100-11. PubMed ID: 26045616
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Water Extract of Dolichos lablab Attenuates Hepatic Lipid Accumulation in a Cellular Nonalcoholic Fatty Liver Disease Model.
    Im AR; Kim YH; Lee HW; Song KH
    J Med Food; 2016 May; 19(5):495-503. PubMed ID: 27152979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Involvement of CYP2E1-ROS-CD36/DGAT2 axis in the pathogenesis of VPA-induced hepatic steatosis in vivo and in vitro.
    Ma L; Wang Y; Chen X; Zhao L; Guo Y
    Toxicology; 2020 Dec; 445():152585. PubMed ID: 33007364
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
    Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
    Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of MD2-dependent inflammation attenuates the progression of non-alcoholic fatty liver disease.
    Zhang Y; Wu B; Zhang H; Ge X; Ying S; Hu M; Li W; Huang Y; Wang L; Chen C; Shan X; Liang G
    J Cell Mol Med; 2018 Feb; 22(2):936-947. PubMed ID: 29077272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.